PATENT Docker

IITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Salah D. KLIVIGHN, et al.

RECEIVED

Serial No.: 09/892,505

Group Art Unit: 1636

NOV 2 5 2002

Filed: June 28, 2001

Examiner: Nguyen, Quang TECH CENTER 1600/2900

PRODUCTION METHOD OF PATTERN FOR CASTING For:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, DC 20231

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

CERTIFICATION PARAGRAPH

The undersigned certifies that no item of information in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any

Serial No.: 09/892,505

individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR 1.97(e)(2).

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 500417 and please credit any excess fees to such deposit account.

Respectfully submitted,

MCDERMOTT, WILL & EMERY

Robert L. Price

Registration No. 22,685

600 13th Street, N.W. Washington, DC 20005-3096 (202) 756-8000 RLP:prp Facsimile: (202) 756-8087

Date: November 22, 2002

INFORMATION DISCLOSURE CITATION IN AN APPLICATION				ATTY. DOCKET NO. 50193-109		SERIAL NO. 09/892,505 RECEIVE	
NOV 2 2 2002 (2) TO-1449)				APPLICANT Salah D. KIVLIGHN, et al. NOV 2 5 2002			
				June 28,	FILING DATE June 28, 2001		ECH CENTER 1600
(A)	M AN	U	.S. PATEN	I DOCUME!	NTS	in the state of th	
EXAMINER'S INITIALS	PATENT NO.	DATE		NAME	CLASS	SUBCLASS	FILING DATE
	5,260,322	11/9/1993	Nakasima et al.				
The state of the s		FOR	EIGN PAT	ENT DOCUM	MENTS		
EXAMINER'S INITIALS	PATENT NO.	DATE	C	COUNTRY	CLASS	SUBCLASS	Translation Yes No
	OTHER	ART (Inclu	ding Autho	r, Title, Date	, Pertinent P	ages, Etc.)	tion of the second
m	Alderman, M.H. et al, "Serum Uric Acid and Cariovascular Events in Successfully Treated Hypertensive Patients", Hypertension 34:144-150 (1999).						
`	Fang, J. et al, "Serum Uric Acid and Cariovascular Mortality", The NHANES I Epidemiologic Follow-up Study, 1971-1992, JAMA 283:2404-2410 (2000).						
	Landmesser, U. et al., "Oxidative stress and vascular damage in hypertension", Coronary Artery Disease, 2001, Sep.; 12, (6): 455-461.						
1	Maxwell, Simon et al., "Anti-oxidants-a protective role in cardiovascular disease?", Expert Opinion, Pharmacother., 2001, Nov.; 2(11): 1737-1750.						
	Marilda Mazzali, et al., "Elevated Uric Acid Increases Blood Pressure in the Rat by a Novel Crystal-Independent Mechanism", pp. 1101-1106.						
M	Nakashima, M., "Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects", Eur J. Clin Pharmacol (1992), 42: 333-335.						
	Nakazono, K. et al., "Does superoxide underlie the pathogenisis of hypertension?", Proc. Natl. Acad. Sci., 88: 10045-10048, 1991.						
	Pui, Ching-Hon et al., "Recombinant Urate Oxidase for the Prophylaxis or Treatment of Hyperuricemia in Patients With Leukemia or Lymphoma", J. Clin. Oncol., (2001), 19: 697-704.						
	Sowers, J.R., "Hypertension, Angiotensis II, and Oxidative Stress", NEJM, 346: (2002), 1999-2001. Vaziri, N.D. et al., "Effect of Antioxidant Therapy on Blood Pressure and NO Synthase Expression in Hypertensive Rats", American Heart Association, 36: (2000) 957-964.						
	Verdecch ia, P. et al., "Relation Between Serum Uric Acid and Risk of Cardiovascular Disease in Essential Hypertension: The PIUMA Study", American Heart Association, 36: (2000) 1072-1078.						
EXAMINE	Wilcox, C.S., "Reactive Oxygen Species: Roles in Blood Pressure and Kidney Function", Current Hypertension Reports, 2002, 160-6. DATE CONSIDERED						
L/M HAITIALIK				ALE CONSIDERED			